U.S. stocks ended down on Monday, led by losses in biotech shares after disappointing news from several companies including Amgen.
The Nasdaq Biotech Index .NBI sank 4.1 percent, its biggest daily percentage loss since March 25, while the S&P Healthcare index .SPXHC, down 1.8 percent, was the biggest drag on the benchmark S&P 500 index.
Amgen shares (AMGN.O) led the S&P 500’s decline, dropping 3.3 percent to $162.38 after U.S. regulators said Amgen’s skin cancer immunotherapy cannot be considered for an accelerated review at this time.
Celladon Corp (CLDN.O) shares fell 80.7 percent to $2.64 and hit a record low of $2.59. It said it expected layoffs and cost cuts after the company’s lead experimental gene therapy to treat heart failure failed a key trial.
Healthcare companies have been the top performers so far in 2015, helping push major stock indexes to records. Biotechs in particular have driven up the Nasdaq, which last week reached its first all-time closing high in 15 years.
The sector is being dragged down by reports of high pricing by specialty pharmaceutical companies as well as the disapponting news from Celladon and Amgen, said Paul Yook portfolio manager of biotech exchange traded funds (BBC.P) and (BBP.P) at LifeSci Partners in New York.
“Drug pricing has been a real concern for investors,” he said.
The Nasdaq biotech sector briefly fell into bear market territory a year ago following a selloff in Gilead (GILD.O) shares and concerns about valuations. But analysts said for now they don’t view Monday’s selloff as the start of a bigger drop. The Nasdaq biotech index is up more than 50 percent since April 2014.
“This run in the biotechs is going to come to end at some point but I’m not panicking yet,” said Bill Gunderson, president of Gunderson Capital in San Diego.
“I don’t think you can look at what’s happening today and say this is the end of the biotech sector. You might just have a big institution reallocating a little bit of money here.”
The Dow Jones industrial average .DJI fell 42.17 points, or 0.23 percent, to 18,037.97, the S&P 500 .SPX lost 8.77 points, or 0.41 percent, to 2,108.92 and the Nasdaq Composite .IXIC dropped 31.84 points, or 0.63 percent, to 5,060.25.
Also in the healthcare space, Mylan (MYL.O) fell 5.7 percent to $71.72 after it rejected Teva Pharmaceutical’s (TEVA.N) unsolicited $40 billion takeover offer, saying it “grossly undervalues” the company. Teva lost 4.3 percent to $61.63.
The Health Care Select Sector SPDR (XLV.P) exchange-traded fund was down 1.8 percent.
Limiting some of the day’s decline, Apple (AAPL.O) shares rose 1.8 percent at $132.65 ahead of its results.
NYSE declining issues outnumbered advancers 1,923 to 1,130, for a 1.70-to-1 ratio; on the Nasdaq, 1,956 issues fell and 805 advanced, for a 2.43-to-1 ratio favoring decliners.
The S&P 500 posted 14 new 52-week highs and 1 new low; the Nasdaq Composite recorded 101 new highs and 42 new lows.